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Abstract 
Zollinger-Ellison syndrome is an often progressive, persistent and frequently life-threatening 
disease, described for the first time as characterized by ulceration of the upper jejunum, 
hypersecretion of gastric acid and non-beta islet cell tumors of the pancreas; this syndrome 
is due to the hypersecretion of gastrin. We report a case of Zollinger-Ellison syndrome 
presenting as severe esophagitis evolving in stenosis, which demonstrates how a delayed 
diagnosis may induce risk of disease spreading. In this setting new diagnostic approaches, 
such as somatostatin receptor scanning and positron emission tomography with 
68 Ga-labeled octreotide, could be particularly useful, as well as further new therapeutic 
options, such as molecular targeted treatments and peptide receptor radionuclide therapy, 
though surgery is currently the only form of curative treatment, and the role of the 
therapeutic options mentioned needs to be clarified by forthcoming studies. 
 
Introduction 
Zollinger-Ellison syndrome (ZES) is an often progressive, persistent and frequently 
life-threatening disease, described for the first time as characterized by ulceration of 
the upper jejunum, hypersecretion of gastric acid and non-beta islet cell tumors of the 
pancreas; this syndrome is due to the hypersecretion of gastrin [1] secondary to a 
gastrinoma. This is a neuroendocrine tumor derived from multipotential stem cells of 
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endodermal origin. It can be sporadic (in 80% of cases) or associated with multiple 
endocrine neoplasia type 1 (MEN1). 70% of gastrinomas arise from the duodenum, the 
remainder from the pancreas or less often from lymph nodes adjacent to the pancreas. 
MEN1 is an autosomal dominant inherited syndrome caused by mutations of the 
MEN1 tumor suppressor gene on chromosome 11q13 [2]. MEN1 gene mutations are 
also identified in 33% of sporadic gastrinomas [3]. MEN1 is characterized by the 
combined occurrence of primary hyperparathyroidism (>90%), pancreaticoduodenal 
endocrine neoplasms (65–75%) and tumors of the anterior pituitary gland (30–65%). 
Pancreaticoduodenal endocrine tumors (PETs) are of outstanding interest because 
malignant PETs represent the most common cause of death within MEN1 syndrome 
[4, 5]. This is especially true for gastrinomas, despite effective control of acid 
hypersecretion and its complications by proton pump inhibitors (PPIs) [6, 7]. 
The incidence of ZES in the United States initially ranged from 0.1 to 1% of patients 
with peptic ulcer disease [8], but this percentage may be underestimated because 
patients with ZES often presented with symptoms similar to those of Helicobacter 
pylori-related disease or to those caused by typical peptic ulcer disease related to 
nonsteroidal anti-inflammatory drugs. In fact these symptoms may be controlled by a 
standard dose of PPIs, thus such patients are not tested for hypergastrinemia [8]. 
ZES is usually diagnosed in the fifth decade of life, and although it may occur in 
children and adolescents or the elderly, it is diagnosed between the age of 20 and 60 in 
90%. The male-to-female ratio ranges between 1.5:1 and 2:1. Over 90% of patient with 
ZES develop peptic ulcers, often solitary ulcers <1 cm in diameter (75% of ulcers in the 
first portion of the duodenum, 14% in the distal duodenum and 11% in the jejunum). 
These ulcers recur much more often than in patients with sporadic ulcer disease. Other 
prominent clinical features are abdominal pain (75%) and diarrhea (73%), which are 
the most frequent symptoms, while heartburn and weight loss are reported by 44 and 
17% of patients. Gastrointestinal bleeding is the initial presentation in 25% of patients, 
while nephrocalcinosis and renal colic are more frequent in MEN1 compared with 
sporadic tumors. Metastatic disease is evident at the time of diagnosis in one third of 
patients with gastrinoma; the liver is the most common site of metastasis [8]. 
For the diagnosis of ZES there are three tests: fasting serum gastrin concentration, 
secretin stimulation test and gastric acid secretion studies. Of these, only the first and 
the second are used routinely. After the diagnosis of ZES is made, the gastrinoma must 
be located and staged [8]. We report a case of ZES presenting as severe esophagitis 
evolving in stenosis, which demonstrates how a delayed diagnosis may induce risk of 
disease spreading. 
Case Report 
A 61-year-old woman was admitted to our hospital with a 3-year history of nausea and vomiting 
not related to food and sometimes associated with watery diarrhea. During the last year she had 
lost about 20% of her body weight (her previous weight was 78 kg, and at admission to our unit her 
weight was 64 kg). Because of worsening of these symptoms she was admitted to our unit. 
In the previous years the patient had been admitted to other hospitals. Esophagogastro-
duodenoscopy had been performed 3 years before, showing a large H. pylori-positive bulbar ulcer 
(treated with eradicant triple therapy) and esophagitis. Abdominal ultrasonography and computed 
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tomography were performed to exclude intestinal disease. These showed some focal hepatic lesions 
which were interpreted as angiomyolipomatosis. The patient was discharged from the hospital and 
treated with PPIs and prokinetics, without any clinical benefit. 
On admission to our unit, esophagogastroduodenoscopy showed severe esophagitis with large 
mucosal ulcerations and an esophageal stenosis (fig. 1). For this reason gastrin and chromogranin 
levels were determined, resulting in values over the upper normal limits (>1,490 mU/ml and 
>540 mU/ml, respectively). ZES was then suspected, so abdominal ultrasonography was performed, 
showing many hepatic focal lesions with a contrastographic pattern of repetitive lesions. 
Octreoscan revealed only many enhancing lesions (somatostatin receptor subtype 2 and 5 
positive) in the liver. The serrated esophageal stenosis did not allow us to perform endoscopic 
ultrasonography to try to find any primary lesions of the pancreas. Abdominal magnetic resonance 
imaging did not detect pancreatic or intestinal lesions, thus a biopsy of the liver lesion was performed 
and the histology diagnosed a gastrinoma. The immunohistochemical profile showed 80% cell 
positivity for gastrin (as shown in fig. 2, with a scale bar of 100 μm) and chromogranin (as shown in 
fig. 3, with a scale bar of 100 μm). In addition, no mutation of the MEN1 gene was found, so MEN1 was 
excluded. 
For this reason total parenteral nutrition and PPI i.v. were started, obtaining a reduction in the 
frequency of vomiting and diarrhea. An endoscopic pneumatic dilation of the esophageal stenosis 
was performed, with an improvement of both dysphagia and esophageal canalization. A further 
endoscopic ultrasonography was performed to detect primary lesions of the pancreas, but the result 
was negative. The patient was discharged with a high-dose PPI therapy, with the program to perform 
periodical esophageal endoscopic dilation and to start chemotherapy with octreotide and receptorial 
radiotherapy with 1,850 MBq of 90Y-Dotatoc. 
Discussion 
This case reported shows that severe necrotic esophagitis unresponsive to a 
standard dosage of PPI may be due to ZES [9]. In the literature few cases of necrotic 
esophagitis have been described [10–12]. The consequence of a delayed diagnosis may 
be severe esophageal stricture and metastatic disease [13, 14], like in our patient. High 
doses of PPI together with endoscopic pneumatic dilation led to resolution of 
esophageal symptoms. 
Little is known about the risk of severe esophagitis in ZES. A prospective study has 
evaluated esophageal involvement and its complications in ZES [8]. The authors show 
that this complication is more severe in ZES associated with MEN1 than in sporadic 
ZES and they also identify important factors for the pathogenesis that need to be 
incorporated into the long-term treatment. In Jensen’s series [8], 10 patients out of 215 
(0.4%) with sporadic ZES developed esophageal strictures. Our case was a sporadic ZES 
which developed strictures. It is possible that the delayed diagnosis was the cause of 
this complication. A high dosage of PPIs together with endoscopic pneumatic dilation 
kept the patients asymptomatic. 
Though the two major modalities for tumor identification are somatostatin 
receptor scanning (SRS) and single photon emission computed tomography, 
particularly useful in identifying liver and bone metastases [15], sometimes the 
identification of gastrinoma is difficult. When a strong clinical suspicion persists 
despite negative results, other techniques have been used in the past, including dual 
phase helical computed tomography, magnetic resonance imaging, angiography, 
arterial stimulation and venous sampling, and fluorodeoxyglucose-positron emission 
tomography (FDG-PET) [16]. To date, with the improvement of the knowledge 
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about the pathophysiology of the disease, further techniques could be used for the 
detection of both primary tumors and metastases. Multi-detector computed 
tomography could be performed not only to demonstrate small primary tumors and 
liver metastases, but also tumor-associated desmoplastic fibrosis around the primary 
tumor and lymph node metastases. Other new approaches performed to visualize 
neuroendocrine tumors are 11C- and 18F-labeled L-Dopa PET, which show a higher 
sensitivity (65%) than FDG-PET (29%) and SRS (57%), but a lower sensitivity than 
morphologic imaging by computed tomography and magnetic resonance imaging 
(73%) and by 11C-5-hydroxytryptophan-PET. PET with 68 Ga-labeled octreotide (such 
as 68Ga-DOTA-TOC, 68Ga-DOTA-NOC and 68Ga-DOTA-TATE) has also been evaluated 
in a few published reports, also showing a higher sensitivity than SRS. In selected cases 
tumor localization can only be achieved through laparotomy by direct palpation, 
duodenal transillumination or intraoperative ultrasound. The precise role of these new 
approaches in the treatment algorithm of neuroendocrine tumors will hopefully be 
clarified by forthcoming studies [17]. 
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Fig. 1. Severe esophagitis with a tight lower esophageal stenosis. 
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Fig. 2. Liver immunohistochemistry with cell positivity for gastrin (arrows), scale bar = 100 μm. 
 
 
 
Fig. 3. Liver immunohistochemistry with cell positivity for chromogranin (arrows), scale bar = 
100 μm. 
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